Jun Yan1, Abhisek Mitra1, Jiemiao Hu1, Jeffery J Cutrera1, Xueqing Xia1, Thomas Doetschman2, Mihai Gagea3, Lopa Mishra4, Shulin Li5. 1. Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 2. BIO5 Institute and Department of Cellular & Molecular Medicine, Tucson, AZ, United States. 3. Department of Veterinary Medicine & Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 4. Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 5. Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: Sli4@mdanderson.org.
Abstract
BACKGROUND & AIMS: Sepsis is an acute systemic inflammatory response to infection associated with high patient mortality (28-40%). We hypothesized that interleukin (IL)-30, a novel cytokine protecting mice against liver injury resulting from inflammation, would generate a protective effect against systemic inflammation and sepsis-induced death. METHODS: Sepsis was induced by lipopolysaccharide (LPS) or cecal ligation and puncture (CLP). The inhibitory effects of IL-30 on septic inflammation and associated therapeutic effects were determined in wild-type, IL30 (p28)(-/-), IL10(-/-), and CD1d(-/-) mice. RESULTS: Mice treated with pIL30 gene therapy or recombinant IL-30 protein (rIL30) were protected from LPS-induced septic shock or CLP-induced polymicrobial sepsis and showed markedly less liver damage and lymphocyte apoptosis than control septic mice. The resulting reduction in mortality was mediated through attenuation of the systemic pro-inflammatory response and augmentation of bacterial clearance. Mice lacking IL-30 were more sensitive to LPS-induced sepsis. Natural killer-like T cells (NKT) produced much higher levels of IL-10 and lower levels of interferon-gamma and tumor necrosis factor-alpha in IL-30-treated septic mice than in control septic mice. Likewise, deficiency in IL-10 or NKT cells abolished the protective role of IL-30 against sepsis. Furthermore, IL-30 induced IL-10 production in purified and LPS-stimulated NKT cells. Blocking IL-6R or gp130 inhibited IL-30 mediated IL-10 production. CONCLUSIONS: IL-30 is important in modulating production of NKT cytokines and subsequent NKT cell-mediated immune regulation of other cells. Therefore, IL-30 has a role in prevention and treatment of sepsis via modulation of cytokine production by NKT.
BACKGROUND & AIMS:Sepsis is an acute systemic inflammatory response to infection associated with high patient mortality (28-40%). We hypothesized that interleukin (IL)-30, a novel cytokine protecting mice against liver injury resulting from inflammation, would generate a protective effect against systemic inflammation and sepsis-induced death. METHODS:Sepsis was induced by lipopolysaccharide (LPS) or cecal ligation and puncture (CLP). The inhibitory effects of IL-30 on septic inflammation and associated therapeutic effects were determined in wild-type, IL30 (p28)(-/-), IL10(-/-), and CD1d(-/-) mice. RESULTS:Mice treated with pIL30 gene therapy or recombinant IL-30 protein (rIL30) were protected from LPS-induced septic shock or CLP-induced polymicrobial sepsis and showed markedly less liver damage and lymphocyte apoptosis than control septic mice. The resulting reduction in mortality was mediated through attenuation of the systemic pro-inflammatory response and augmentation of bacterial clearance. Mice lacking IL-30 were more sensitive to LPS-induced sepsis. Natural killer-like T cells (NKT) produced much higher levels of IL-10 and lower levels of interferon-gamma and tumor necrosis factor-alpha in IL-30-treated septic mice than in control septic mice. Likewise, deficiency in IL-10 or NKT cells abolished the protective role of IL-30 against sepsis. Furthermore, IL-30 induced IL-10 production in purified and LPS-stimulated NKT cells. Blocking IL-6R or gp130 inhibited IL-30 mediated IL-10 production. CONCLUSIONS:IL-30 is important in modulating production of NKT cytokines and subsequent NKT cell-mediated immune regulation of other cells. Therefore, IL-30 has a role in prevention and treatment of sepsis via modulation of cytokine production by NKT.
Authors: Alejandro Villarino; Linda Hibbert; Linda Lieberman; Emma Wilson; Tak Mak; Hiroki Yoshida; Robert A Kastelein; Christiaan Saris; Christopher A Hunter Journal: Immunity Date: 2003-11 Impact factor: 31.745
Authors: Stefan Wirtz; Ingrid Tubbe; Peter R Galle; Hans J Schild; Mark Birkenbach; Richard S Blumberg; Markus F Neurath Journal: J Exp Med Date: 2006-07-31 Impact factor: 14.307
Authors: Jeongho Park; Jonathan H DeLong; James J Knox; Christoph Konradt; Elia D Tait Wojno; Christopher A Hunter Journal: Infect Immun Date: 2019-11-18 Impact factor: 3.441
Authors: Carlo Sorrentino; Zhinan Yin; Stefania Ciummo; Paola Lanuti; Li-Fan Lu; Marco Marchisio; Matteo Bellone; Emma Di Carlo Journal: J Immunother Cancer Date: 2019-07-31 Impact factor: 13.751